SARADHA CHEXAL, MD

CURRENT ADDRESS

Work: Retina Consultants of Austin, PA
3705 Medical Parkway, Suite 410
Austin, Texas 78705
512-454-5851

Retina Research Center
3705 Medical Parkway, Ste 420
Austin, Texas 78705
512-279-1251

EMPLOYMENT

Retina Research Center — Austin, TX
September 2014-present

Retina Consultants of Austin, PA — Austin, TX
Private practice- Retina — September 2014-present

FELLOWSHIP

JULES STEIN EYE INSTITUTE, UCLA — Los Angeles, CA
Retina — July 2013-2014

RESIDENCY

UNIVERSITY OF SOUTH FLORIDA — Tampa, FL
Dept. of Ophthalmology — July 2010 – July 2013

- Awarded Chief Resident 2012-2013

ST. VINCENT'S HOSPITAL MANHATTAN — New York, NY
Dept. of Internal Medicine — July 2009 – July 2010

- Medical internship

EDUCATION

NEW YORK MEDICAL COLLEGE — Valhalla, NY
M.D. — 2005 - 2009

- Awarded $15,000 grant from the Friends of the Congressional Glaucoma Caucus Foundation to start the NYMC chapter of the Student Sight Savers Program – provided free glaucoma screenings to the local community
- AOA Pathology / Microbiology tutor

UNIVERSITY OF FLORIDA — Gainesville, FL
B.S., Microbiology (cum laude) — 2002 – 2005

- UF Honors Program Scholarship – full tuition

- Graduated in 3 years

MANUSCRIPTS

- *Treatment of Choroidal Melanoma by Vitrectomy, Fine Needle Aspiration Biopsy, I-125 Plaque Brachytherapy, and Silicone Oil.* Lyons L, Chexal S, Berger B. To be submitted.

- *Retinal Cavernous hemangioma and Arnold Chiari Malformation Type 1: a case report.* Lyons L, Chexal S. Retina today 2017.

- *En face OCT imaging in Multiple Evanescent White Dot Syndrome.* Pichi F, Chexal S, et al Sarraf D. Retina December 2016. Volume 36, p178-188.

- *Choroidal involvement in Acute Posterior Placoid Pigment Epitheliopathy.* Mrejen S, Chexal S, Sarraf D, Freund B. Osli Retina.2016.

- *Gender and Hereditary Eye Disease: A Review.* Iragavarapu S, Gorin MB. Current Eye Research. August 2014.

- *Birdshot Retinochoroidopathy.* Iragavarapu, S. Grand Rounds Presentation. **www.eyewiki.com.** 2012 June 19.

- *Forme fruste anterior segment dysgenesis.* Abanitt MR, Romano A, Iragavarapu S, Budenz DL, Lee RK. Br J Ophthalmol. 2010 Aug 30.

- *ETX1 is over-expressed in the glaucomatous trabecular meshwork.* Iragavarapu S, Algeciras ME, Lee RK, Bhattacharya SK. Mol Vis 2009 Oct 16;15:2061-7.

- *ARVO* Abstract Title: Localized Expression of Disco-Interacting Protein 2 Homolog (Dip2A) in Human Eyes. Author block: *T.K. Lee, S. Iragavarapu, G. Gaidosh, R.K. Lee, S.K. Bhattacharya.* U. of Miami Miller School of Medicine, Bascom Palmer Eye Institute, Miami, FL. 2008.

CLINICAL RESEARCH

Sub-Investigator: A Phase 1, Multicenter, Open-Label, Single-Dose and Multiple-Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravitreal Injections of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration – (NGM Biopharmaceuticals Inc. NGM621)

Sub-Investigator: A Multi-Center, Non-randomized, Open-label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7200220 in Monotherapy and in Combination with ranibizumab Following Intravitreal Administration in Patients with Diabetic Macular Edema - (Roche BP40899 Dovetail)

Sub-Investigator: A Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and

Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) who are Carriers of High-Risk Genetic Complement Variants Associated with Dry Age-related Macular Degeneration (AMD) (Gemini GEM-NH-001)

Sub-Investigator: A Prospective Natural History Study to Evaluate Clinical Characteristics and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) who are Carriers of High-Risk Genetic Variants of Complement Factor H - (Gemini GEM-NH-002)

Sub-Investigator: A Phase 1/1b Open-label, Multi-Center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects with Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retina Vein Occlusion (RVO) - (Kodiak KSI-CL-101)

Sub-Investigator: A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) – (Apellis APL2-303)

Sub-I Investigator: A Multicenter, Randomized, Double-Masked, Phase 3a study to Assess Safety and Efficacy of brolucizumab 6mg q4 weeks Compared to Aflibercept 2mg q4weeks in Patients with Neovascular Age-Related Macular Degeneration with Persistent Retina Fluid (MERLIN) - (Novartis Merlin)

Sub-Investigator: A Multi-Center, Non-Randomized, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200394 Following Intravitreal Administration in Patients with Neovascular Age-Related Macular Degeneration -(Roche BP40923)

Sub-Investigator:: A Phase 2, Randomized, Placebo Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-L_{RX}, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) – (Ionis 696844-CS5)

Principal Investigator: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to
Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (Lucerne) – **(**Genentech GR40844 Lucerne)

Sub-Investigator: A Randomized, Active-Controlled, Patient and Investigator-Masked, Multiple Dose Proof-of-Concept Study of Intravitreal LKA651 in Patients with Diabetic Macular Edema - (Novartis LKA651x2202)

Principal Investigator: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess
Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO) – (Genentech GR40973)

Sub-Investigator: Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects with Type 2 Diabetes (FOCUS) (Novo Nordisk Focus)

Sub-Investigator: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to

Evaluate the Safety, Efficacy and Pharmacokinetics of Sucutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy (Stealth SPIAM-202)

Sub-Investigator: Randomized Clinical Trial Assessing the Effects of Pneumatic Vitreolysis on Vtireomacular Traction –(DRCR AG)

Sub-Investigator:: Single-Arm Study Assessing the Effects of Pneumatic Vitreolysis on Macula Hole (DRCR AH)

Sub-Investigator: A Randomized, Double-Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants with Neovascular Age-Related Macular Degeneration (AMD)- **(**Panoptica PAN-01-102)

Sub-Investigator: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration – (Genentech GR40549 Portal)

Sub-Investigator: A Phase III, Multicenter, Randomized, Visual Assessor-Masked Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration - (Genentech GR40548 Archway)

Sub-Investigator: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema – (Genentech GR40349 Yosemite)

Sub-Investigator: A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema - (Novartis CRTH258B2301 Kestrel)

Principal Investigator: A Randomized, Masked, Controlled, Trial to Study the Safety and Efficacy of Suprachoridal CLS-TA in Combination with an Intravitreal Anti-VEGF Agent in Subjects with Retinal Vein Occlusion – (Clearside CLS1003-302 TOPAZ)

Sub-Investigator: A Phase 1, Open-label, Multicenter, Dose Escalation study to Evaluate the safety of a Single Intravitreal injection of THR-149 for Treatment of Diabetic Macular Edema (DME) – (Thrombogenics THR-149-001

Sub-Investigator: A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Iconic IT-004)

Sub- Investigator: A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Wet Age-related Macular Degeneration (Santen 36-002 Avante)

Sub-Investigator: A Dose-ranging Study of Intravitreal OPT-302 in Combination with

Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age Related Macular Degeneration (wet AMD) (Opthea OPT-302-1002)

Sub-Investigator: A Randomized Sham-Controlled Double-Masked Phase 2a study of the Efficacy, Safety and Tolerability of the Intravitreal Plasma Kalikrein Inhibitor, KVD001, in Subjects with Center-Involving Diabetic Macular Edema (ciDME) who have had prior Anti-VEGF treatment (Kalvista KVD001-201)

Sub-Investigator: PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate versus Placebo (DRCR Protocol AD)

Sub-Investigator Randomized Trial of Intravitreous Aflibercept versus Intravitreous Bevacizumab+ Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema (DRCR Protocol AC)

Sub-Investigator: Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy (DRCR Protocol AB)

Sub-Investigator: A Phase I/II Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects with Neovascular Age-Related Macular Degeneration (Graybug GBV-102-001)

Sub-Investigator: A Randomized, Double-Masked, Placebo-Controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 weeks with a 12 week follow up period in patients with Non-proliferative diabetic retinopathy without center-involved diabetic macular edema (Boehringer-Ingelheim 1386.12 Robin)

Sub-Investigator: Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg twice daily for 12 months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy (Aerpio AKB-9779-CI-5001 Time-2b)

Sub-Investigator: A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2 (Neurotech NTMT-03-B Renexus)

Sub-Investigator: A Natural History Observation and Registry Study of Macular Telangiectasia Type 2 (The Lowy Medical Research Institute, Mactel Project)

Sub-Investigator: A Phase IIa Trial Of TLC399 (ProDex) in Subjects with Macular Edema due Retina Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability (Taiwanese Liposome Company TLC399 ProDex)

Sub-Investigator: A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy **(**Regeneron Pharmaceuticals, Inc. VGFTe-OD-1411 Panorama)

Sub-Investigator: A Multicenter, Open-label, Extension Study to Evaluate the Long-Term Safety and

Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration who have Completed a Roche-Sponsored Study (Genentech GX30191 Omaspect)

Sub-Investigator: Simultaneous Blockade of Angiopoietin-2 and VEGF-A with the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration (F. Hoffman-La Roche Ltd., CR29521 Stairway)

Sub-Investigator: A Phase II, Multicenter, Randomized, Active-Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (F. Hoffman-La Roche Ltd, GX28228 Ladder)

Sub-Investigator: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated with Proliferative Diabetic Retinopathy (Acucela Inc., 4439-203)

Sub-Investigator: A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration (Santen Inc., PAVE study)

Sub-Investigator: A Randomized, Double Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration (Regeneron Pharmaceutical, Inc, R910-3-AMD-1517 ONYX)

Sub-Investigator: A Multiple-Center, Multiple-Does, Randomized, Active Comparator-Controlled, Double-Masked, Parallel-Group, 28-Week Study to Investigate the Safety, Tolerability, Pharmaokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Diabetic Macular Edema (Genentech BP30099 Boulevard)

Sub-Investigator: Intravitreous Anti-VEGF Treatment for Prevention of Vision Threating Diabetic Retinopathy in Eyes at High Risk (DRCR Protocol W)

Sub-Investigator: Genes in Diabetic Retinopathy Project (DRCR Genetics)

Sub-Investigator: A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Genentech BP29647 Avenue)

Sub-Investigator: Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (DRCR Protocol S)

Sub-Investigator: Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity (DRCR Protocol V)

Sub-Investigator: Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for

Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes (DRCR Protocol U)

Sub-Investigator: A Phase 2 Multicenter, Randomized, Controlled, Double-Masked Clinical Trial Designed to Evaluate the Safety and Exploratory efficacy of Luminate® (ALG-1001) as Compared to Avastin® in the Treatment of Diabetic Macular Edema (Allegro Ophthalmics, LLC, DME 202B)

Sub-Investigator: An open-label single ascending dose and randomized double-masked, ranibizumab controlled, safety, tolerability, and efficacy study of intravitreal LMG324 in subjects with neovascular age-related macular degeneration (Alcon Research, LTD, LMG324-2201)

Sub-Investigator: A randomized, multi-center, single masked, sham controlled, proof-of-concept study of intravitreal CLG561 as a monotherapy and in combination with LFG316 in subjects with geographic atrophy (Alcon Research, LTD, CLG561-2201)

Principal Investigator: A Phase 4 Safety Study of IOP Signals Inpatients Treated with Iluvien® (Fluocinolone Acetonide Intravitreal Implant) 0.19 MG (Alimera Sciences, Inc., M-01-15-004)

Principal Investigator: Prospective, Multicenter Post-Approval Study (PAS) of Visioncare's Implantable Miniature Telescope (By Dr. Isaac Lipshitz) in Patients with Bilateral Severe to Profound Central Vision Impairment Associated with End-Stage Age-Related Macular Degeneration (VisionCare Ophthalmic Technologies, IMT-PAS-01)

Sub-Investigator: Clinical Study Protocol Phase 1 Dose Escalation and Expansion Study of DS-7080a in Subjects with Neovascular Age-Related Macular Degeneration (Daiichi Sankyo Pharma Development, DS7080-A-U101)

Sub-Investigator: A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects with Neovascular Age-Related Macular Degeneration (Alcon Research, Ltd., RTH258-E003)

Sub-Investigator: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA) - FILLY – (Apellis Pharmaceuticals, Inc., POT-CP121614)

Sub-Investigator: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus *prn* Eylea® Compared to *prn* Eylea® Monotherapy in Neovascular AMD (Tyrogenex, Inc., X82-OPH-201)

Sub-Investigator: A Phase II Proof-of-Concept Study of the Safety and Efficacy of HuCNS-SC Subretinal Transplantation in Subjects with Geographic Atrophy of Age-Related Macular Degeneration (StemCells, Inc., CL-AMD-201)

Sub-Investigator: Prospective, observational longitudinal study addressing Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time (DRCR AA)

Sub-Investigator: A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration (Alcon Research Ltd. RTH258-C001)

Sub-Investigator: A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Iconic Therapeutics IT-002)

Sub-Investigator: A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (Astellas Pharma Europe B.V. VIDI)

Sub-Investigator: A randomized, parallel group, double-masked, active-controlled Phase 1/2 clinical trial to evaluate the efficacy and safety of dexamethasone sodium phosphate Visulex system for the treatment of non-infectious anterior uveitis (Aciont, Inc. DSPV-201)

Sub-Investigator**:** A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patient with Geographic Atrophy Secondary to Age-Related Macular Degneration (Genentech GX29176 Chroma)

Sub-Investigator: Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: A Multicenter, Prospective, Randomized Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 weeks with Intravitreal Aflibercept Every 4 weeks (SCORE2)

Sub-Investigator: A Randomized, Double Masked, Placebo Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration (University of Virginia Department of Ophthalmology TOGA)

Sub-Investigator: A Phase 1 Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD) (Panoptica PAN-90806)

Sub-Investigator: A Phase 2, Randomized, Active- Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema (Aerpio AKB-9778):

Sub-Investigator: Ocriplasmin Research to Better Inform Treatment (Thrombogenics TG-MV-018 ORBIT**)**

Sub-Investigator: A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDG-F Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration (Ophthotech Corp. OPH1003)

Sub-Investigator: A prospective, Two Cohort, Single-Masked, Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects with Exudative Age-Related Macular Degeneration (Alcon C-13-001 ESBA1008)

Sub-Investigator: An Open-Label, Non-randomized, Single-Arm, Roll-Over Study to Continue Dosing

of Gevokizumab in Non-Infectious Intermediate, Posterior, or Pan- Uveitis Patients Who Each Successfully Completed either the X052130 or the X052131Study (XOMA X052132)

Sub-Investigator: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (XOMA X052130)

Sub-Investigator: A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled with Systemic Treatment (XOMA X052131)